the highest and lowest rates of decline in estimated glomerular filtration rate. Results. The mean eGFR slope was 2.2 (1.4) and −5.1 (1.2) mL/min/1.73 m 2 in the stable kidney function group and the rapid progression group, respectively. CpG islands in NPHP4, IQSEC1 and TCF3 were hypermethylated to a larger extent in subjects with stable kidney function (P-values of 7.8E−05 to 9.5E−05). These genes are involved in pathways known to promote the epithelial to mesenchymal transition and renal fibrosis. Other CKD-related genes that were differentially methylated are NOS3, NFKBIL2, CLU, NFKBIB, TGFB3 and TGFBI, which are involved in oxidative stress and inflammatory pathways (P-values of 4.5E−03 to 0.046). Pathway analysis using Ingenuity Pathway Analysis showed that gene networks related to cell signaling, carbohydrate metabolism and human behavior are epigenetically regulated in CKD. Conclusions. Epigenetic modifications may be important in determining the rate of loss of kidney function in patients with established CKD.
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I N T RO D U C T I O N
Chronic kidney disease (CKD) is a global epidemic, which often leads to end-stage renal disease (ESRD). However, our understanding of the underlying risk factors and pathophysiologic pathways associated with the progression of CKD remain largely unknown. It is becoming increasingly clear that a better understanding of CKD and its associated outcomes cannot be achieved without a better understanding of genetic contributions to the processes. Indeed, familial aggregation studies, comparisons of incidence rates between different racial or ethnic populations and segregation analysis suggest that the progression of renal disease has a strong genetic component [1] [2] [3] . However, many genome-wide association studies-identified risk alleles for CKD suggest they confer a very small relative risk [4] , leading to looking beyond traditional genetics to explain the 'missing heritability' [5] .
Epigenetics refers to a heritable change in the pattern of gene expression that is mediated by a mechanism specifically not due to alterations in the primary nucleotide sequence [6] . DNA methylation is the most common epigenetic modification and is a major regulator of transcriptional activity [7, 8] .
In fact, a growing number of human diseases have been reported to be associated with aberrant DNA methylation [7] [8] [9] [10] . Identification of epigenetic gene pathways is very important and highly relevant to personalized medicine because unlike sequence variations, epigenetic modifications are potentially reversible.
We compared the genome-wide DNA methylation profile in selected Chronic Renal Insufficiency Cohort (CRIC) study participants, who experienced rapid decline in kidney function to those whose kidney function remained stable or improved during follow-up. We identified differential methylation involving a number of loci that may be involved in the progression of CKD.
S U B J E C T S A N D M E T H O D S

Patient selection
The CRIC study is a prospective, multi-center observational cohort study established in 2001 [11] . Males and females between the ages of 21 and 74 years with an estimated glomerular filtration rate (eGFR) of 20-70 mL/min/1.73 m 2 at the time of eligibility assessment during the screening visit were enrolled. Participants were excluded for pregnancy, New York Heart Association class III-IV heart failure, human immunodeficiency virus infection, cirrhosis, myeloma, renal cancer, recent chemotherapy or immunosuppressive therapy, polycystic kidney disease and organ transplantation or previous treatment with dialysis for at least 1 month. The institutional review boards at each site approved the study and all the participants provided written informed consent. A total of 3939 study participants were enrolled in the study. Details regarding the design of the study have been previously published [11] .
We selected 40 CRIC study participants to study; 20 with the highest rate of decline in eGFR ('rapid progression group') and 20 with the lowest rate of decline ('stable kidney function group'). Subjects with acute kidney injury were excluded. The slope of eGFR was determined by a mixed effects linear regression model using a minimum of two measures of eGFR. The model included random intercepts and random slopes for each participant without adjusting for other covariates. The intercepts and slopes follow normal distribution with mean of 0 and unknown variance. We use a stratified weighted sampling strategy to ensure that each group was similar with respect to race (non-Hispanic white and African Americans only), sex, diabetic status and stages of CKD at baseline. Diabetes was defined as fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL or use of insulin or anti-diabetic medication. Hypertension at entry was defined as either systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg or use of antihypertensive medications.
Serum creatinine was measured by the Jaffe method on a Beckman Synchron System (Beckman Coulter, Brea, CA, USA) and calibrated to the Cleveland Clinic standard. eGFR was computed using the four-variable Modification of Diet in Renal Disease Study equation. Serum cystatin C was measured on a Dade-Behring BNII (Siemens Healthcare Diagnostics, Inc., Tarrytown, NY, USA), with a coefficient of variation of CV of ∼1.7%. Proteinuria was quantitated from 24-h urine protein excretion. Cytokine levels were measured using standard ELISA (Quantikine HS, R&D Systems, Minneapolis, MN, USA).
Global DNA methylation studies Genomic DNA was extracted from whole blood samples using the Puregene Whole Blood DNA Isolation kit (Gentra Systems, Inc., MN, USA) and stored using standard techniques. The Infinium HumanMethylation 450 BeadChip (Illumina, Inc., San Diego, CA, USA), which includes 485 577 cytosine positions in the human genome, was utilized for genome-wide DNA methylation screening. The probes recognize at least 20 216 transcripts, potential transcripts or isolated CpG islands. Genomic DNA (500 ng) from each sample was treated by bisulfite conversion with the EZ DNA Methylation Kit (Zymo Research Corporation, Irvine, CA, USA) according to manufacturer recommendations. After enzymatic fragmentation, 4 μL of DNA (150 ng) was hybridized to the BeadChips. The chips were scanned with an Illumina HiScanSQ system that employs a two-color laser (532 nm/660 nm) fluorescent scanner with a 0.375 μm spatial resolution. The intensities of the images were extracted using Genome Studio (2011.1) Methylation Module (v1.8). The methylation score for each CpG is represented as a β-value according to the fluorescent intensity. The β-values are between 0 (unmethylated) and 1 (completely methylated) and can be interpreted as the percentage of methylation for the particular CpG site.
Quality control analysis
The primary endpoint of our analysis was to identify CpG sites with significantly different methylation between the rapid progressors and the stable kidney function group. First, we performed quality control analysis to obtain a clean dataset for analysis. Quality control P-values were calculated to identify failed probes as per Illumina's recommendations. All of the 450 K methylation arrays exceeded our quality threshold of <5% failed probes. Raw data from the arrays were normalized using Illumina's control probe scaling procedure, [12] with background subtracted using the Methylation Module v1.8 in the Illumina Genome Studio 2011.1 software.
The Infinium HumanMethylation 450 BeadChip tests the methylation status of 485 577 cytosine positions in the human genome. We cleaned the normalized methylation dataset to improve the quality of our data analysis. We removed CpG sites from the analysis that were located on the X and Y chromosome, [12] [13] [14] that contained a single nucleotide polymorphism (SNP), or that contained an SNP within 10 base pairs of the methylation probe [12] . We focused only on CpG sites within known CpG islands obtained from the UCSC database (n = 247 806). The CpG sites in the UCSC database were discovered using a modified method from GardinerGarden and Frommer [15] .
The β-values from the cleaned dataset were imported into Partek Genomics Suite (version 6.6; Partek Incorporated, St Louis, MO, USA) for further quality control. The β-values were logit transformed (M-values) to resolve the problem of heteroscedasticity in the high and low ranges of methylation (<0.2 and ≥0.8) [16] . The M-value is calculated as the log2 ratio of the intensities of the methylation probes versus unmethylated probe. In addition, we removed noise from our analysis by examining only CpG islands with an M-value (β-value) of ≥0.01 (≥0.1).
Data analysis
The data were analyzed using an analysis of covariance (ANCOVA) model, with M-value for each site as the dependent variable and response (rapid progression versus stable kidney function) as the independent variable. In each ANCOVA model, covariates included sex, race (African American or non-Hispanic white American) and diabetes status (diabetic or non-diabetic). This model allowed us to test whether the mean M-value for each site was significantly different between those with rapid progression and those with stable kidney function while adjusting for the effect of sex, race and diabetes. Percent difference (% Diff ) was calculated to show the difference in the methylation level between the rapid progressors and stable kidney function group using the following formula: [(Beta ValueRapid − Beta ValueStable)/(Average of Beta ValueRapid and Beta ValueStable)]*100. A false discovery rate (FDR) correction was implemented, but none of the identified CpG islands remained significant after adjustment.
Pathway analysis
The list of CpG islands passing the P-value <0.05 (n = 7664 CpG sites) for differential β-values between the different groups were imported into the program Ingenuity Pathway Analysis (IPA) software, Build 124019 (Ingenuity Systems, Inc., Redwood City, CA, USA), for pathway generation. This number of filtered CpG sites represented 3527 genes, since some genes were represented by multiple CpG sites. For this analysis in IPA, we focused on only human species and networks that are experimentally validated with the literature. 
R E S U LT S
Clinical and biochemical characteristics
The clinical and biochemical characteristics of the study population at baseline are shown in Table 1 . The mean eGFR slope was 2.2 (1.4) and −5.1 (1.2) mL/min/1.73 m 2 in the stable kidney function group and the rapid progression group, respectively. The stable kidney function group actually had a positive slope of eGFR, illustrating an improvement in eGFR during the follow-up. The rapid progression group had lower hemoglobin and serum calcium, and higher fibrinogen levels compared with the stable kidney function group.
Methylation analysis
We examined the degree of methylation of CpG sites in individuals with rapid progression of kidney disease compared with individuals with stable kidney function for sites with a P-value <0.05 (n = 7664 CpG sites). We defined the degree of methylation using a beta (β) value, where any value less than one is the percentage of methylation at that CpG site. A β-value of ≥0.5 is hypermethylated while a β-value <0.5 is hypomethylated. In the rapid progressors, 6471 CpG sites (84%) were hypermethylated and 1193 CpG sites (16%) were hypomethylated. In the stable kidney function group, 6496 CpG sites (85%) were hypermethylated and 1168 CpG sites (15%) were hypomethylated.
We also compared the degree of methylation between the rapid progressors and the stable kidney function group. We found 6107 CpG sites had a higher degree of hypermethylation in individuals with stable kidney function compared with rapid progressors, representing 80% of CpG sites. Only 1225 CpG sites had a higher degree of methylation in the rapid progressors compared with the stable kidney function group (16% of CpG sites).
Top CpGs associated with rapid progression of kidney disease The top CpG sites associated with a high rate of decline in kidney function, with P-values <1.0E−05, are listed in Table 2 . These sites had the largest difference in methylation between the 'rapid progressors' and the 'stable kidney function group'. Fourteen of the 15 CpG sites (93%) had a higher degree of hypermethylation in the stable kidney function group compared with rapid progressors ( Table 2 ). The CpG sites that were identified were within genes involved in renal tubular development and function, regulation of cell adhesion and actin cytoskeleton remodeling, transcriptional repression and regulation of peroxisomes (P-values ranging from 2.4E−05 to 9.5E−05). Genes with the most functional relevance to progression of kidney disease included nephronophthisis 4 (NPHP4), IQ motif and Sec7 domain 1 (IQSEC1) or GEP 100 and transcription factor 3 (TCF3), which are involved in the regulation of the epithelial to mesenchymal transition. After adjustment for multiple comparisons using FDR, these CpG sites no longer reached statistical significance. We also found that a CpG in the clusterin (CLU) gene had a higher degree of hypermethylation in the stable kidney function group when compared with the rapid progressors (P-value of 0.010). Furthermore, CpGs within NOS3, TGFB3, CARS2, DNMT3A, TGFBI and two genes from the NF-κB family (NFKBIL2 and NFKBIB) were hypermethylated in the stable kidney function group (Table 3; P-values ranging from 6.6E−04 to 0.046).
Pathway analysis
We performed pathway analysis in order to identify the most relevant pathophysiological pathways related to loss of kidney function using IPA. The gene network with genes involved in human behavior, cell signaling and carbohydrate metabolism was the top contender, as shown in Figure 1 and Table 4 .
D I S C U S S I O N
In this study, we compared the genome-wide DNA methylation profiles of the CRIC study participants who had experienced rapid decline in kidney function to those who had stable kidney function or improvement in kidney function. We identified a distinct set of epigenetic signatures in subjects with rapid decline in kidney function, including key genes NPHP4, IQSEC1 and TCF3, which are involved in pathways known to promote the epithelial to mesenchymal transition. Pathway analysis identified specific epigenetic pathways related to rapid loss of kidney function.
DNA methylation is generally associated with silencing of gene expression, whereas active genes are usually unmethylated or hypomethylated. The epigenome is the interface of genetics and environment, where plasticity of epigenetic code modifies the rigid genetic code to determine the phenotype [17] . Once a critical proportion of nephron is lost, non-specific glomerular and tubulointerstitial scarring, characteristic of all forms of CKD, may result from a common pathway of mechanisms [18] . Current evidence indicates that the process of epithelial mesenchymal transition (EMT) allows a fully differentiated epithelial cell to assume the phenotype of matrixproducing fibroblasts and myofibroblasts leading to renal fibrosis. Epigenetic changes have been shown to be involved in the orchestration of EMT and eventual renal fibrosis [19] [20] [21] [22] . Genome-wide methylation analysis identified hypermethylation of genes involved in pathways known to promote the epithelial to mesenchymal transition: NPHP4, IQSEC1 and TCF3 (Table 2) . NPHP4 is involved in renal tubular development and function, which is an essential protein in a complex 
O R I G I N A L A R T I C L E
E p i g e n e t i c s o f C K D p r o g r e s s i o n The β-values are between 0 (unmethylated) and 1 (completely methylated), and can be interpreted as the percentage of methylation for the particular CpG site. A β-value ≥0.5 represents a CpG site that is hypermethylated while a β-value <0.5 represents a CpG site that is hypomethylated.
c CpG site had a higher degree of hypomethylation in the stable kidney function group compared with rapid progressors. All other CpGs were hypermethylated to a larger extent in the stable kidney function group compared with the rapid progressors.
located in actin and microtubule structures that function in cell-cell and cell-matrix adhesion signaling [23] . Disrupting the function of NPHP4 may contribute to renal fibrosis and cystogenesis in nephronophthisis [24] . IQSEQ1 or p100 interacts and activates ADP-ribosylation factor 6 (ARF6) for regulation of cell adhesion and actin cytoskeleton. In normal rat kidney cells, p100 overexpression causes F-actin to disappear, thereby acting through ARF6 regulation of adhesion junction dynamics and actin remodeling [25] . In addition, suppression of TCF3, an E2A transcription factor, leads to transforming growth factor-β (TGF-β)-controlled EMT changes, such as α-smooth muscle actin and E-cadherin expression, and alterations in cell morphology and cytoskeletal arrangement [26] . In addition, we found that the CpG site within the CLU gene is hypermethylated to a higher degree in the stable kidney function group when compared with rapid progressors. Increased expression of this gene has been shown previously to be associated with loss of kidney function [27] . Rapid progressors could potentially have higher expression of CLU, and thus may be important in the progression of CKD. There is substantial evidence that inflammatory processes are involved in the progression of CKD [28] . Indeed, in CRIC study participants, biomarkers of inflammation were negatively associated with measures of kidney function and proteinuria [29] . The activation of immune response is a highly coordinated multi-step process that involves epigenetic changes [30] . We found that two CpG probes within genes of the NF-κB pathway (NFKBIL and NFKBIB) that were hypermethylated (Table 3) . NFKBIL is part of the IκB family, which acts as an inhibitor of NF-κB by shutting down its activity and stopping activation target genes in the nucleus [31] . NFKBIB acts as a transcriptional activator by complexing with NF-κB; The β-values are between 0 (unmethylated) and 1 (completely methylated), and can be interpreted as the percentage of methylation for the particular CpG site. A β-value ≥0.5 represents a CpG site that is hypermethylated while a β-value <0.5 represents a CpG site that is hypomethylated. c CpG site had higher degree of hypermethylation in the rapid progressors compared with the stable kidney function group. All other CpGs were hypermethylated to a larger extent in the stable kidney function group compared with the rapid progressors.
F I G U R E 1 : Top network of genes associated with rapid progression of CKD. 
E p i g e n e t i c s o f C K D p r o g r e s s i o n it functions as a chaperone, moving NF-κB into the nucleus and preventing IκB inhibitors from turning off its activity [32] . NFKBIB was hypermethylated to a larger extent in the stable kidney function group, where NF-κB activity could potentially be lower than in rapid progressors, slowing progression of CKD. We also identified two genes within the TGF-β superfamily, TGF-β3 and TGF, beta-induced (TGFB3 and TGFBI; Table 3 ). TGFB1 signaling can cause a multitude of changes within the kidney including loss of epithelial cell adhesions and disruption of the tubular basement membrane, leading to renal fibrosis [22] . TGFB3 also promotes fibrosis in renal cells, primarily mediated through TGFB1 pathways [33] . TGFBI acts in the extracellular matrix, where it plays a role in cell adhesion and migration. A study by Lee et al. [34] showed that this gene is up-regulated in the kidneys of diabetic rats and high glucosetreated human proximal tubular epithelial cells, illustrating that it may play a role in diabetic nephropathy. The CpGs for these two genes were hypermethylated to a larger extent in the stable kidney function group when compared with the rapid progressors.
Early studies investigating the role of global methylation in CKD have used different methodologies to study methylation differences, as well as different inclusion criteria to select their study population. Ingrosso et al. [35] recruited men with hyperhomocysteinemia treated with dialysis. These patients had global hypomethylation as measured by an enzymatic assay. Treatment with folate restored DNA methylation and normalized expression to levels found in the control group. Stenvinkel et al. [36] studied methylation differences in three different groups of patients based on degree of renal failure. Using luminometric methylation assay (LUMA), the authors showed that CKD patients with inflammation had global DNA hypermethylation compared with non-inflamed CKD patients and normal controls. We used the Infinium HumanMethylation 450 BeadChip to study methylation differences in patients with stable kidney function and patients with rapid decline in kidney function. We found that CpG sites in the stable kidney function group had a higher degree of hypermethylation (80% of CpG sites) compared with the rapid progressors.
Methylation studies, including our study, cannot be directly compared with each other due to difficult standardization of methylation methodologies. Different methods used to extract DNA from tissues and cells could lead to differences in the cell population used in methylation studies. Imprinted genes have been shown to have tissue-specific DNA methylation patterns [37] . Therefore, our study could have shown different global DNA methylation results from previous studies due to the use of a different method to extract DNA from blood cells, resulting in slight variations in the cell population studied. Different methodologies used in methylation studies can also result in unequal detection of various types of modified DNA, such as 5-methylcytosine and the oxidized form of 5-methylcytosine, otherwise known as 5-hydroxylmethylcytosine (5-hmC) [38] . 5-hmC may be important in development [39] and may be involved in disease progression. The LUMA assay used by Stenvinkel et al. [36] and the Illumina Infinium HumanMethylation 450 K BeadChip cannot detect 5-hmC modifications. However, the enzymatic method used by Ingrosso et al. is able to detect all methylated cytosines, including the 5-hmC modifications. Different inclusion criteria for the recruitment of subjects for various studies results in distinct patient populations, which further complicates comparison between methylation studies. These limitations illustrate that the value of global DNA methylation as a disease progression marker is unclear, at least at present. A more promising approach would be to identify specific genes that could potentially contribute to the pathophysiology of progression of CKD that may be deregulated by methylation differences, which we have investigated in the present study.
Two previous studies have investigated DNA methylation using the Illumina Human methylation 27 BeadChip, which successfully identified several CpG sites in patients with ESRD and diabetic nephropathy [13, 40] . We also found different methylation patterns based on response (stable kidney function versus rapid loss of kidney function) in CpGs within phosphatidylinositol glycan anchor biosynthesis, class U (PIGU), runt-related transcription factor 3 (RUNX3), negative elongation factor complex member B (COBRA1) and deathassociated protein kinase 3 (DAPK3), which had increased methylation in stable kidney function diabetic patients compared with rapid progressors with diabetes (data not shown). RUNX3 and COBRA1 are involved in transcription regulation, PIGU functions in glycosylphosphatidylinositol (GPI)-anchor biosynthesis and DAPK3 induces apoptosis [40] . A study by Bell et al. [40] also illustrated methylation association in the HIST1H3I gene, involved in nucleosome assembly. In our study, we noted differential methylation of several CpGs in HIST1H2BK, HIST1H4B, HIST1H4H, HIST1H3E, HIST1H1T, HIST1H2BD and HIST1H1T in subjects with diabetes, which are located in the same region on chromosome 6 and are involved in nucleosome assembly (data not shown).
IPA was used to identify molecular pathways related to CKD progression. The top network from this analysis included genes which function in human behavior, cell signaling and carbohydrate metabolism ( Figure 1 and Table 4 ). These results illustrate that we were able to successfully identify methylation differences in specific genes that are involved in rapid decline in renal function in subjects with CKD.
Our study has a number of strengths and limitations. We used the Infinium HumanMethylation 450 K BeadChip, which offers genomic coverage at an unprecedented level with >485 577 CpG loci represented among coding genes alone. The average gene is represented by 15 probes, with many CpG island containing genes represented with more CpG sites. The Infinium HumanMethylation 450 K BeadChip cannot detect 5-hmC modifications. However, they account for only a small fraction of total methylated sites [41] .
Although the study subjects were rigorously selected from a large pool of patients with varying level of renal function, the number of patients studied is small. We performed stringent normalization and filtering methods, looking only at CpGs within CpG islands and excluding chromosomes X and Y, yet our most significant CpGs associated with progression of CKD did not pass FDR correction.
There are epigenetic differences between tissues, the extent of which is yet unclear [42] . Under ideal conditions, the epigenetic changes should be studied in specific renal cell types. However, DNA derived from peripheral blood mononuclear cells (PBMC) is increasingly recognized as a viable surrogate for diseases processes occurring in organ-specific diseases such as renal disease, atherosclerosis and diabetes [36, [43] [44] [45] [46] [47] [48] . This is particularly relevant to the present study because infiltrating mononuclear cells are intimately involved in the progression of CKD [49] . Substantial evidence supports the role of infiltrating macrophages in renal fibrosis through phenotypic transition [50, 51] . There is also evidence that epigenetic modifications are key to the EMT [19] . Furthermore, Talens et al. [52] investigated whether genomic DNA from existing biobanks is suitable for the identification of these risk factors in epidemiological studies. They concluded that for the large majority of candidate loci, inter-individual differences in the cellular composition of the blood sample did not contribute to the variation observed in DNA methylation, or explained only a minor proportion of this variation. Bell et al. [40] used PBMC derived DNA and identified 19 CpG sites associated with risk of diabetic nephropathy.
Inflammation is known to influence methylation status [53] [54] [55] . Epigenetic regulation of cytokines and transcription factors have been shown to be important in directing lineage differentiation of Th1 and Th2, as well as Tregs, which determines the immune response, [56] and by extension inflammation [54] . In our study, rapid progressors had increased levels of inflammatory markers compared with the stable kidney function group (Table 1) . It is possible that inflammation differences may account for some of the methylation differences between the rapid progressors and the stable kidney function group. Gupta et al. [29] showed that inflammation levels are higher in CRIC subjects that had lower eGFR and higher proteinuria. Finally, we did not perform gene expression studies, which could have given insight about the functional significance of the cognate genes.
In summary, we investigated the DNA methylation pattern associated with rapid loss of kidney function in a representative sample of CKD subjects selected from participants in a large observational cohort study, and identified differential methylation in CpG islands of several genes that are associated with rapid loss of kidney function. The most functionally relevant epigenetic signatures in subjects with a rapid decline in kidney function included key genes NPHP4, IQSEC1 and TCF3, which are involved in pathways known to promote the epithelial to mesenchymal transition. Thus, epigenetic modifications may play an important regulatory role in loss of kidney function through expression or suppression of key pathway genes.
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